文献速递神经核医学核素与放射性配体治疗

对流增强递送靶向或非靶向197gHg金纳米颗粒治疗小鼠胶质母细胞瘤

Treatment of Human Glioblastoma Multiforme in NRG Mice by Convection-Enhanced Delivery of EGFR-Targeted or Nontargeted Auger Electron-Emitting 197gHg-Labeled Gold Nanoparticles.
PubMed 文献 · J Nucl Med · 2026-08-03

在NRG小鼠原位胶质母细胞瘤模型中,经对流增强递送(CED)给予发射俄歇电子的EGFR靶向panitumumab-197gHg-AuNPs或非靶向197gHg-AuNPs,评估其有效性与安全性。结果显示两种放射性纳米药物均局限于输注部位,无全身毒性;靶向组肿瘤更小、中位生存期更长(59天 vs 43天 vs 对照31-33天),且肿瘤细胞核自吸收剂量更高(40.2 Gy vs 12.2 Gy)。

要点

  • CED递送197gHg-AuNPs局限于脑内输注部位,未分布至健康脑组织或其他器官。
  • 靶向panitumumab-197gHg-AuNPs组中位生存期59天,显著长于非靶向组43天和对照组31-33天。
  • 靶向组肿瘤细胞核俄歇电子自吸收剂量40.2 Gy,为非靶向组12.2 Gy的3.2倍。

核心结论

  • EGFR靶向panitumumab-197gHg-AuNPs经CED治疗NRG小鼠U251-Luc人GBM肿瘤比非靶向197gHg-AuNPs更有效,可能为GBM提供安全有效的治疗并改善患者生存。

研究设计与样本

  • 在NOD-Rag1nullIL2rgnull(NRG)小鼠原位GBM肿瘤模型中,经CED给予panitumumab-197gHg-AuNPs或非靶向197gHg-AuNPs,用SPECT/CT评估197gHg定位。
  • 毒性评估:CED给予1.8×10^11至2.3×10^11个panitumumab-197gHg-AuNPs(0.9±0.5 MBq)或非靶向197gHg-AuNPs(2.6±0.8 MBq),监测血液学、血生化和体重。
  • 疗效评估:U251-Luc荷瘤小鼠分别接受panitumumab-197gHg-AuNPs(1.3±0.3 MBq)、197gHg-AuNPs(1.1±0.4 MBq)、panitumumab-AuNPs、AuNPs或0.9% NaCl,用MRI和Kaplan-Meier中位生存期评估肿瘤反应。

主要发现

  • panitumumab-197gHg-AuNPs和197gHg-AuNPs均局限于输注部位,未重新分布至健康脑组织或其他器官。
  • 无血液学、肝脏或肾脏毒性,体重无下降。
  • 21天和34天MRI显示,panitumumab-197gHg-AuNPs或197gHg-AuNPs治疗组肿瘤显著小于panitumumab-AuNPs、AuNPs或0.9% NaCl组。
  • panitumumab-197gHg-AuNPs组中位生存期59天,显著长于非靶向197gHg-AuNPs组43天和对照组31-33天。
  • GBM肿瘤细胞核俄歇电子自吸收剂量:panitumumab-197gHg-AuNPs组40.2 Gy,为非靶向197gHg-AuNPs组12.2 Gy的3.2倍。

临床怎么用

  • 该临床前结果提示EGFR靶向197gHg-AuNPs经CED可能安全有效地治疗GBM并改善生存,但尚需临床转化验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The effectiveness and safety of Auger electron (AE)-emitting epidermal growth factor receptor (EGFR)-targeted panitumumab-197gHg-gold nanoparticles (AuNPs) or nontargeted 197gHg-AuNPs for treating glioblastoma multiforme (GBM) were studied after convection-enhanced delivery (CED) in NOD-Rag1nullIL2rgnull (NRG) mice with orthotopic GBM tumors. We hypothesized that EGFR binding, internalization, and nuclear importation of panitumumab-197gHg-AuNPs would make these radiation nanomedicines more effective than nontargeted 197gHg-AuNPs because of the subcellular range of AEs, but that both would be safe because of their confined localization at the infusion site in the brain after CED. Methods: Localization of 197gHg in NRG mice after CED was assessed by SPECT/CT imaging. Toxicity was evaluated after CED of 1.8 × 1011 to 2.3 × 1011 panitumumab-197gHg-AuNPs (0.9 ± 0.5 MBq) or nontargeted 197gHg-AuNPs (2.6 ± 0.8 MBq) by hematology, blood biochemistry, and body weight monitoring. Mice with U251-Luc tumors were treated with panitumumab-197gHg-AuNPs (1.3 ± 0.3 MBq) or 197gHg-AuNPs (1.1 ± 0.4 MBq), panitumumab-AuNPs or AuNPs, or 0.9% NaCl. Tumor response was assessed by MRI and Kaplan-Meier median survival. Self-absorbed doses in the nucleus of tumor cells from AEs were estimated. Toxicity to the brain was assessed by MRI and ex vivo histologic examination. Results: Both panitumumab-197gHg-AuNPs and 197gHg-AuNPs were confined to the infusion site with no redistribution to healthy brain or other organs. There was no hematologic, liver, or kidney toxicity and no decrease in body weight. MRI at 21 d and 34 d revealed that tumors in mice treated with panitumumab-197gHg-AuNPs or 197gHg-AuNPs were significantly smaller than tumors in mice treated with panitumumab-AuNPs, AuNPs, or 0.9% NaCl. Median survival in mice treated with panitumumab-197gHg-AuNPs (59 d) was significantly longer than that in mice treated with nontargeted 197gHg-AuNPs (43 d) or control treatments (31-33 d). The self-radiation absorbed dose in the nucleus of GBM tumor cells from AEs was 3.2-fold higher for panitumumab-197gHg-AuNPs (40.2 Gy) than for 197gHg-AuNPs (12.2 Gy). Conclusion: EGFR-targeted panitumumab-197gHg-AuNPs were more effective than nontargeted 197gHg-AuNPs for treating U251-Luc human GBM tumors in NRG mice. This approach may offer a safe and effective treatment for GBM that could improve patient survival.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Brown MK, Cai Z, Ganga-Sah Y, et al. Treatment of Human Glioblastoma Multiforme in NRG Mice by Convection-Enhanced Delivery of EGFR-Targeted or Nontargeted Auger Electron-Emitting 197gHg-Labeled Gold Nanoparticles. J Nucl Med. 2026. PMID: 42276782. doi:10.2967/jnumed.125.271785

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。